BI-765063 is under clinical development by Boehringer Ingelheim International and currently in Phase I for Oral Cavity (Mouth) Cancer. According to GlobalData, Phase I drugs for Oral Cavity (Mouth) Cancer does not have sufficient historical data to build an indication benchmark PTSR for Phase I. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the BI-765063 LoA Report. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
BI-765063 (OSE-172) is under development for the treatment of solid tumors including recurrent head and neck squamous cell carcinoma (HNSCC), oral cavity cancer, oropharyngeal cancer, hypopharyngeal cancer, laryngeal cancer, metastatic colorectal cancer and hepatocellular carcinoma. The drug candidate is a second generation check point inhibitor. It acts by targeting cells expressing SIRP-alpha (Signal Regulatory Protein alpha) and CD47. It is administered through intravenous route. The drug candidate was also under development for mesothelioma, renal cell carcinoma, melanoma, non-small cell lung cancer, pancreatic cancer, head and neck squamous cell carcinoma, urothelial carcinoma, small cell lung cancer, gastric cancer, triple negative breast cancer and ovarian cancer.
Boehringer Ingelheim International overview
Boehringer Ingelheim International (Boehringer), a subsidiary of CH Boehringer Sohn AG & Co KG, is a pharmaceutical company that develops, manufactures and markets of pharmaceuticals, parasiticides, vaccines and therapeutics for unmet medical needs. It offers a wide range of products including human diseases, animal health care products and biopharmaceuticals. The company’s products are used for the treatment central nervous system disorders, cardiometabolic diseases, respiratory diseases, cancer, immunology, and retinal diseases among others. It also offers animal healthcare products for Swine, Ruminant, Poultry, Horses, Pets etc. It operates facilities for manufacture pharmaceuticals and medical products. Boehringer is headquartered in Ingelheim am Rhein, Rheinland-Pfalz, Germany.
For a complete picture of BI-765063’s drug-specific PTSR and LoA scores, buy the report here.